ProCE Banner Activity

CE

Targeted Treatment of B-Cell Malignancies: Practical Strategies for BTK Inhibitors

Video

Watch this interactive video recording from a live webinar to review key pharmacist and nursing considerations in the use of BTK inhibitors for CLL and MCL.

Nurses: 1.00 Nursing contact hour, including 1.00 hour of pharmacotherapy credit 

Pharmacists: 1.00 contact hour (0.1 CEUs)

Released: February 01, 2023

Expiration: January 31, 2024

No longer available for credit.

Share

Faculty

Karen M. Fancher

Karen M. Fancher, PharmD, BCOP

Associate Professor of Pharmacy Practice
Duquesne University School of Pharmacy
Clinical Pharmacy Specialist, Oncology
University of Pittsburgh Medical Center Passavant
Pittsburgh, Pennsylvania

Anthony Perissinotti

Anthony Perissinotti, PharmD, BCOP

Hematology Clinical Pharmacist Specialist
Clinical Team Leader
, Hematology/Oncology
Adjunct Clinical Assistant Professor
University of Michigan, Michigan Medicine
Roger Cancer Center
Ann Arbor, Michigan

Provided by

ProCE Banner
ProCE Banner

Supporters

Supported by an educational grant from

Pharmacyclics LLC, an AbbVie Company

Partners

National Association of Specialty Pharmacy

ProCE Banner

Target Audience

This activity is intended for pharmacists and nurses, including specialty pharmacists and nurses, who care for patients with CLL/SLL and MCL, as well as pharmacy directors, chief pharmacy officers, and other stakeholders in specialty pharmacy.

Learning Objectives

After completing this activity, participants should be better able to:

  • Analyze current evidence on the mechanistic properties, safety, and efficacy of first-generation and next-generation BTK inhibitors with therapeutic applications in CLL/SLL or MCL

  • Recommend evidence-based management plans for treatment-naive patients with CLL/SLL or MCL, taking into consideration guidelines, expert recommendations, and recent practice-changing clinical trial results

  • Manage toxicities associated with BTK inhibitor therapy to support adherence, appropriate dosing, and treatment continuation and to maximize patient survival and quality of life

  • Discover treatment paradigm shifts in the management of patients with CLL/SLL or MCL with progression on a covalent BTK inhibitor with resistance mutations or the inability to continue therapy due to adverse events

Disclosure

Clinical Care Options, LLC (CCO) and ProCE, LLC require instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO and ProCE policy. CCO and ProCE are committed to providing their learners with high-quality CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company. Faculty disclosures will be provided prior to the start of the CE activity.

Karen M. Fancher, PharmD, BCOP: consultant/advisor/speaker: AstraZeneca, BTG Specialty Pharmaceuticals, G1 Therapeutics, 
LP Pharmaceuticals, Merck.

Anthony Perissinotti, PharmD, BCOP: consultant: AbbVie, BeiGene, Janssen, Pfizer, Rigel, Sanofi, Servier.

The planners and content peer reviewers from Clinical Care Options, LLC, ProCE, LLC, and National Association of Specialty Pharmacy (NASP) do not have any relevant financial relationships to disclose

Instructions for Credit

Learners wishing to earn CE/CME credit must: 

  1. View the content in its entirety
  2. Relate the content material to the learning objectives 
  3. Complete evaluation form 

The estimated time to complete this activity is 1.00 hours.

Successful completion of the post-test is required to earn CE/CME credit.
Successful completion is defined as a cumulative score of 65%.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Learners have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by healthcare professionals without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities

Accreditation

Joint Accreditation Statement
Joint AccreditationIn support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Nursing Continuing Professional Development
The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1.0 contact hour.

Pharmacists

This activity is jointly provided by ProCE, LLC, Clinical Care Options, LLC, and the National Association of Specialty Pharmacy (NASP). ProCE, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-9999-22-211-H01-P has been assigned to this home study application-based activity (initial release date 11-03-2022). This CE activity is approved for 1.0 contact hour (0.10 CEU) in states that recognize ACPE providers. This CE activity is provided at no cost to participants. Completion of the evaluation and the post-test with a score of 65% or higher are required to receive CE credit. No partial credit will be given. Statements of completion will be issued online at www.ProCE.com, and proof of completion will be posted in NABP CPE Monitor profiles.

Additional Information

This activity has been made available online.